The company?s revenue is trending slightly below our previous forecast, driven by a steeper-than-expected decline in COVID-19-related sales and continued bioprocessing inventory challenges. For the full year 2023, we now expect total revenue to decline by a mid-single digit percent rate (compared with our previous forecast of low-single digit percent growth) as mid-single-digit percent core sales growth and acquisition revenue only partially offset the decline in COVID-19-related testing, vaccines, and therapeutics sales. We expect S&P Global Ratings-adjusted EBITDA margin to decline approximately 250 basis points to about 34%, compared with our previous expectation of about 35%, as sales and marketing expenses and labor costs increase. We expect Danaher to pursue acquisitions to further strengthen its competitive position in bioprocessing and
